Colchicine in Acute Myocardial Infarction: “Teaching New Tricks to an Old Dog”

Abbate, Antonio; Mauro, Adolfo G; Thurber, Clinton J.

doi:10.4172/2161-1025.1000e133

Cited by 1 publication

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With these mechanisms, colchicine interferes with Interleukin-1beta production [14]. Consistent with the central role of NALP3 in the inflammation process and thereby in induced inflammatory injuries, colchicine has gained attention as a potential therapeutic agent in several other indications in the field of rheumatology and cardiology [11].…”

Section: Repurposing Of Drugs For Faster Acquisition Of Therapies For...mentioning

confidence: 93%

“…Colchicine is one of the oldest anti-inflammatory drugs used to treat arthritis and gout. For several years it was also used as an unapproved drug to treat Mediterranean fever (FMF) [11]. Most of colchicine activities were attributed to dysfunctioning of the cytoskeleton due to the binding of colchicine to tubulin, thereby inhibiting microtubule formation.…”

Section: Repurposing Of Drugs For Faster Acquisition Of Therapies For...mentioning

confidence: 99%

See 1 more Smart Citation

Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine

Valencic

Šmid

Tommasini

et al. 2018

CMC

View full text Add to dashboard Cite

Human primary immunodeficiency diseases (PIDs) are a large group of rare diseases and are characterized by a great genetic and phenotypic heterogeneity. A large subset of PIDs is genetically defined, which has a crucial impact for the understanding of the molecular basis of disease and the development of precision medicine. Discovery and development of new therapies for rare diseases has long been de-privileged due to the length and cost of the processes involved. Interest has increased due to stimulatory regulatory and supportive reimbursement environments enabling viable business models. Advancements in biomedical and computational sciences enable the development of rational, designed approaches for identification of novel indications of already approved drugs allowing faster delivery of new medicines. Drug repositioning is based either on clinical analogies of diseases or on understanding of the molecular mode of drug action and mechanisms of the disease. All of these are the basis for the development of precision medicine.

show abstract

Section: Repurposing Of Drugs For Faster Acquisition Of Therapies For...mentioning

confidence: 93%

Section: Repurposing Of Drugs For Faster Acquisition Of Therapies For...mentioning

confidence: 99%

Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine

Valencic

Šmid

Tommasini

et al. 2018

CMC

View full text Add to dashboard Cite

show abstract

Colchicine in Acute Myocardial Infarction: “Teaching New Tricks to an Old Dog”

Cited by 1 publication

References 11 publications

Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine

Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine

Contact Info

Product

Resources

About